A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
12/2004
12/30/2004	US20040265376 Orally deliverable; enhanced bioavailability; encapsulated in dissolution resistant material
12/30/2004	US20040265362 Adhesive, skin and/or nail permeation enhancer; drug contained in contact layer; and binders, crosslinking agents, softeners, solvents, fillers and/or antioxidants; occlusive backing; fungal infection treatment of onychomycosis
12/30/2004	US20040265357 Combination of liponic acid and glutamine in food and pharmaceutical products
12/30/2004	US20040265342 Desensitizing a patient to polypeptide allergen by administering a peptide derived from allergen to induce a late phase response in an individual who possesses major histocompatibility complex Class II molecule; immunotherapy; vaccines
12/30/2004	US20040265336 Multivalent vaccination using recombinant adenovirus
12/30/2004	US20040265332 BASB029 polynucleotide(s) and polypeptides from Neisseria meningitidis
12/30/2004	US20040265331 BASB027 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
12/30/2004	US20040265328 Identifying polypeptide antigens that bind to sera raised against commensal bacterial proteins
12/30/2004	US20040265327 Method of immunomodulation using thione-forming disulfides
12/30/2004	US20040265320 Administering a compound selected from 3-O-(3',3'-dimethylsuccinyl) betulinic acid, 3-O-(3',3'-dimethylsuccinyl) betulin, 3-O-(3',3'-dimethylglutaryl) betulin, 3-O-(3',3'-dimethylsuccinyl) dihydrobetulinic acid, 3-O-(3',3'-dimethylglutaryl) betulinic acid, (3',3'-dimethylglutaryl) dihydrobetulinic acid
12/30/2004	US20040265319 Geranyl-geranyl acetone as an active ingredient for treating influenza virus infection
12/30/2004	US20040265303 Anti-CCR2 antibodies and methods of use therefor
12/30/2004	US20040265300 Targeting cancer cell; induction or prevention of apoptosis in eukaryotic cells; a fusion peptide contains a viral apoptotic peptide and an antibody fragment; recombinant host cell comprising the vector, encoding chimeric polypeptide; bioassay monitoring apoptosis activity; drug target
12/30/2004	US20040265281 System capable of treating and defining various diseases using stem cells
12/30/2004	US20040265280 Phoma sp. SANK 13899 (FERM BP-6851) strain; produce fungicide through fermentation process; obtained from a soil sample collected in Chichi-island, Ogasawara-mura, Tokyo
12/30/2004	US20040265272 Mammalian cell-infecting virus vector encoding epitope-bound beta2m and utilization thereof
12/30/2004	US20040265270 recombinant; Interferons; stabilized with a polyol, a non-reducing sugar or a amino acid; acetate buffer, albumin; mannitol, saccharose and glycine; storage stability
12/30/2004	US20040265241 Methods for the inhalation administration of antibiotics
12/30/2004	US20040261190 Hydrazono-malonitriles
12/30/2004	CA2469140A1 Hcv regulated proteins
12/29/2004	WO2004113372A1 MODIFIED BORDETELLA ADENYLATE CYCLASE COMPRISING OR LACKING CD11b/CD18 INTERACTION DOMAIN AND USES THEREOF
12/29/2004	WO2004113365A2 Hepatitis c serine protease tri-peptide inhibitors
12/29/2004	WO2004113360A1 Phosphoromidates of nucleoside analogues-reproduction inhibitors for human immunodeficient virus
12/29/2004	WO2004113357A2 Nucleoside analog inhibitors of reverse transcriptase
12/29/2004	WO2004113350A1 Cross-linked glycopeptide - cephalosporin antibiotics
12/29/2004	WO2004113329A1 Oxazole derivatives as antibacterial agents
12/29/2004	WO2004113319A1 Novel chromene compound
12/29/2004	WO2004113318A1 Flavanone compound and uses thereof
12/29/2004	WO2004113311A1 Amorphous und crystal forms of (5-chloro-2-{2-
12/29/2004	WO2004113290A1 Substituted alkylamides
12/29/2004	WO2004112804A1 Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections
12/29/2004	WO2004112775A1 Composition for preventing urinary system infections
12/29/2004	WO2004112773A1 Pharmaceutical compositions used for immune disease treatment and improvement
12/29/2004	WO2004112765A1 Method for inhibiting the growth of antibiotic-resistant of bacteria by using pentane-1,5-diol
12/29/2004	WO2004112762A2 Pharmaceutical formulations of amyloid inhibiting compounds
12/29/2004	WO2004099175A3 Blockers of the quorum sensing system of gram-negative bacteria
12/29/2004	WO2004089357A3 Anti-fungal formulation of triterpene and essential oil
12/29/2004	WO2004087067A3 Treatment of aspergillus infections with thymosin alpha 1
12/29/2004	WO2004002940A8 Inhibitors of hcv ns5b polymerase
12/29/2004	WO2003103671A8 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
12/29/2004	WO2003086453A8 Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis
12/29/2004	WO2003057178A3 Viral capsid assembly intermediates
12/29/2004	WO2003015797A8 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
12/29/2004	WO2002043648A3 Compounds active at the glucocorticoid receptor ii
12/29/2004	WO2000061774A3 Bone morphogenic proteins
12/29/2004	EP1491208A1 Stabilized liquid polypeptide-containing pharmaceutical compositions
12/29/2004	EP1491195A1 Pharmaceutical formulations comprising amoxicillin and clavulanate
12/29/2004	EP1491194A1 Vdac regulator
12/29/2004	EP1491192A1 Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon
12/29/2004	EP1491093A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
12/29/2004	EP1490519A2 Life sciences business systems and methods
12/29/2004	EP1490473A1 Bacterial spores
12/29/2004	EP1490409A1 Modified saccharides having improved stability in water
12/29/2004	EP1490407A1 Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
12/29/2004	EP1490406A1 Costimulatory molecule and its use
12/29/2004	EP1490405A2 ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF
12/29/2004	EP1490396A2 Immunogenic hiv peptides for use as reagents and vaccines
12/29/2004	EP1490395A1 Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
12/29/2004	EP1490382A1 Process of preparing azithromycin and crystalline 9-deoxo-9a-aza-9a-homoerythromycin a hydrate used therein
12/29/2004	EP1490373A1 Inhibitors of nucleoside phosphorylases and nucleosidases
12/29/2004	EP1490368A2 2,2-bis(hydroxymethyl)cyclopropylidenemethyl - purines and -pyrimidines as antiviral agents
12/29/2004	EP1490366A1 Novel alkoxypyridine-derivatives
12/29/2004	EP1490365A1 Azaindoles as inhibitors of c-jun n-terminal kinases
12/29/2004	EP1490364A1 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
12/29/2004	EP1490358A1 6-(4-substituted-anilino)pyrimidine derivatives, method for the preparation thereof and antiviral pharmaceutical composition comprising the same
12/29/2004	EP1490352A1 Synthesis of piperidine and piperazine compounds as ccr5 antagonists
12/29/2004	EP1490350A1 Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase
12/29/2004	EP1490343A1 New aryl imidazoles and related compounds as c5a receptor modulators
12/29/2004	EP1490341A1 Novel adamantane derivatives
12/29/2004	EP1490339A1 Novel chalcone derivatives and uses thereof
12/29/2004	EP1490336A1 Piperidine or 8-aza-bicyclo(3.2.1)oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5)
12/29/2004	EP1490317A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/29/2004	EP1490315A1 Controlling chemical reactions by spectral chemistry and spectral conditioning
12/29/2004	EP1490106A2 Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations
12/29/2004	EP1490105A2 Multiple and multivalent dna vaccines in ovo
12/29/2004	EP1490102A1 Fuel additive
12/29/2004	EP1490096A1 Use of hydrogen peroxide producing enzyme for treatment of otitis media
12/29/2004	EP1490094A1 Antibody fusion proteins: effective adjuvants of protein vaccination
12/29/2004	EP1490072A1 Novel therapeutical use of agonist ligands specific to g2a receptor
12/29/2004	EP1490070A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
12/29/2004	EP1490065A1 Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
12/29/2004	EP1490064A1 Substituted pyridinones as modulators of p38 map kinase
12/29/2004	EP1490059A1 Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
12/29/2004	EP1490051A1 Use of topoisomerase inhibitors and heat shock protein 90 inhibitors for use in chemotherapy
12/29/2004	EP1490044A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
12/29/2004	EP1490037A1 Taste masked veterinary solid compositions
12/29/2004	EP1490027A1 Methods for entrapment of bioactive agent in a liposome or lipid complex
12/29/2004	EP1490015A2 Novel 2-amino-9-((2-hydroxymethyl) cyclopropylidenemethyl) purines as antiviral agents
12/29/2004	EP1489924A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
12/29/2004	EP1489915A1 Treatment and prevention of inflammatory disorders
12/29/2004	EP1414836B1 Process for the preparation of l-ribavirin
12/29/2004	EP1343516A4 Analogues of thiocoraline and be-22179
12/29/2004	EP1334094B1 Cholesterol lowering benzo[b]thiophenes and benzo[d]isothiazoles
12/29/2004	EP1265891B1 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
12/29/2004	EP1255821B1 Protein c derivatives
12/29/2004	EP1244444B1 Process for formulation of carbapenem antibiotic compositions
12/29/2004	EP1230224B1 Substituted 5-benzyl-2,4-diaminopyrimidines
12/29/2004	EP1226138B1 Fab i inhibitors
12/29/2004	EP1196616B1 Replication-competent anti-cancer vectors
12/29/2004	EP1196180B1 Treatment of angiogenesis dependent conditions with dextrin sulphate

1 ... 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 ... 1798